A third gene therapy spinoff from Nationwide Children’s Hospital has been acquired, this time for $165 million.
Myonexus Therapeutics Inc. this week released promising results from tests in children of a therapy for a form of muscular dystrophy. Then Sarepta Therapeutics Inc., a publicly traded Boston-area biotech company, moved more than a year early to exercise its option to purchase the startup. It had made a down payment of $60 million last May.
The sale brings a return for the Columbus pediatric hospital, Rev1 Ventures, CincyTech and foundations, parents and patients who invested in Myonexus. I’ve left a message with the hospital seeking comment.
Click here to read the complete article.
Story excerpt provided by Columbus Business First.
Written by Carrie Ghose.
Originally published February 28, 2019.